Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.70 |
| ▸ | HTR1A | P08908 | 5/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 3/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8428871 | 1.00 | CA2 (0.70) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL8426890 | 1.00 | CA2 (0.70) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL4823723 | 0.82 | CA2 (0.75) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL6346222 | 0.82 | CA2 (0.75) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL5274616 | 0.82 | CA2 (1.00) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL4970970 | 0.78 | CA2 (0.68) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL7346088 | 0.78 | CA2 (0.68) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL6348557 | 0.78 | CA2 (0.68) | CA2HTR1ASIGMAR1ADRA2AADRA2B | |
| SCHEMBL4489707 | 0.76 | CYP1A2 (0.38) | CA2 | |
| SCHEMBL4489705 | 0.76 | CYP1A2 (0.38) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0448254-B1 | Process and intermediates for 2R-benzyl-chroman-6-carbaldehyde | PFIZER (US) | 1995-01-18 | — | — | EP | claimed |
| EP-0448254-A2 | Process and intermediates for 2R-benzyl-chroman-6-carbaldehyde | PFIZER INC. (US) | 1991-09-25 | — | — | EP | claimed |
| EP-4134364-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11884680-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| EP-4134364-A2 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-4134364-A2 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| EP-3640241-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2022-09-28 | — | — | EP | disclosed |
| CN-108558889-B | Bromodomain inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2021-11-05 | — | — | CN | disclosed |
| US-10941160-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-23 | — | — | US | disclosed |
| WO-2015058160-A1 | BROMODOMAIN INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2015-04-23 | — | — | WO | disclosed |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-23 | — | — | US | disclosed |
| EP-0888327-B1 | BENZOPYRAN DERIVATIVES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | MENARINI LAB (ES) | 2002-06-12 | — | — | EP | disclosed |
| US-5990142-A | ANTIINFLAMMATORY AGENTS AND ANTIALLERGENS HAVING GOOD ORAL ADSORPTION AND BIOAVAILABILITY; CARDIOTONIC AND ANTIISCHEMIC AGENTS | LABORATORIOS MENARINI S.A. (ES) | 1999-11-23 | — | — | US | disclosed |
| US-5925662-A | OXIDASE INHIBITORS | SYNTHELABO (FR) | 1999-07-20 | — | — | US | disclosed |
| EP-0888327-A1 | BENZOPYRAN DERIVATIVES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | LABORATORIOS MENARINI S.A. (ES) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034885-A1 | BENZOPYRAN DERIVATIVES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | LABORATORIOS MENARINI S.A. (ES) | 1997-09-25 | — | — | WO | disclosed |
| US-5089637-A | PROCESS AND INTERMEDIATES FOR 2R-BENZYL-CHROMAN-6-CARBALDEHYDE | PFIZER INC. (US) | 1992-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | CA2 3892/4885HTR1A 4461/4885SIGMAR1 4496/4885 |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | CA2 3892/4885HTR1A 4461/4885SIGMAR1 4496/4885 |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | CA2 3892/4885HTR1A 4461/4885SIGMAR1 4496/4885 |
| US-10941160-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | CA2 3892/4885HTR1A 4461/4885SIGMAR1 4496/4885 |
| US-11884680-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | CA2 3892/4885HTR1A 4461/4885SIGMAR1 4496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.